L-NMMA
Trials 37
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01791816 | Feb 2013 → Dec 2022 | postural orthostatic tachycardia syndrome, syncope, familial vasovagal | New York Medical College | Completed | No outcome recorded |
| Phase 117 trials | ||||||
| Phase 1 | NCT03066115 | Dec 2020 → Dec 2021 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03236935 | Aug 2018 → Oct 2021 | DNA repair disease, classic Hodgkin lymphoma, head and neck squamous cell carcinoma, melanoma +2 | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT02936687 | Jan 2017 → Jul 2021 | metabolic syndrome X | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT01860911 | Apr 2013 → Aug 2016 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01122407 | Jan 2010 → Nov 2016 | hypertensive disorder, obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 1 | NCT00580619 | Apr 2007 → Jan 2017 | myalgic encephalomeyelitis/chronic fatigue syndrome, orthostatic hypotension, postural orthostatic tachycardia syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00327080 | May 2006 → Mar 2009 | HIV infectious disease | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 1 | NCT00690534 | Sep 2005 → Aug 2012 | muscular atrophy | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1 | NCT00095472 | Nov 2004 → Aug 2007 | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1 | NCT00076414 | Jan 2004 → Sep 2005 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00072826 | Nov 2003 → Aug 2007 | sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00185003 | Jan 2003 → Jun 2005 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00004575 | Feb 2000 → Oct 2001 | — | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1 | NCT00345137 | — | autosomal dominant polycystic kidney disease, glomerulonephritis | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 1 | NCT00344734 | — | congestive heart failure | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 1 | NCT00344916 | — | cirrhosis of liver | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02834403 | Nov 2016 → Jan 2021 | triple-negative breast carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05660083 | Jan 2023 → Dec 2026 expected | metaplastic breast carcinoma, triple-negative breast carcinoma | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT00406731 | Jan 2008 → Nov 2014 | — | Medical University of Vienna | Withdrawn | No outcome recorded |
| Phase 2 | NCT00508989 | Jul 2007 → Dec 2010 | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00048477 | Oct 2002 → Nov 2003 | — | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00166166 | Jul 2002 → Jan 2013 | hyperlipidemia | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT00431392 | Sep 2001 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT00009581 | Jan 2001 → Jan 2003 | sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00112281 | May 2005 → Jan 2007 | cardiogenic shock | Arginox Pharmaceuticals | Terminated | Missed primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT01701973 | Jan 2013 → May 2017 | obesity disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT00410085 | Jan → Nov 2005 | obstructive sleep apnea syndrome | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase not applicable8 trials · 1 met primary | ||||||
| — | NCT02183779 | Jun 2014 → Oct 2016 | Raynaud disease | University Hospital, Grenoble | Unknown | No outcome recorded |
| — | NCT01617551 | Mar 2012 → Mar 2014 | essential hypertension | Regional Hospital Holstebro | Unknown | No outcome recorded |
| — | NCT01060930 | Mar → Jun 2010 | — | University of Edinburgh | Completed | No outcome recorded |
| — | NCT00685945 | Dec 2007 → Jan 2009 | obesity disorder | Vanderbilt University | Completed | Met primary |
| — | NCT00759707 | Apr 2006 → Dec 2009 | peripheral arterial disease | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00240058 | Jul 2005 → Jun 2006 | hypertensive disorder | Crystal A. Gadegbeku | Completed | No outcome recorded |
| — | NCT00180063 | Oct 2003 → Sep 2005 | — | Technical University Dresden | Completed | No outcome recorded |
| — | NCT00178919 | Aug 2002 → Aug 2008 | hypertensive disorder, pure autonomic failure | Vanderbilt University | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT00708357 Background | May 2005 → Dec 2009 | — | Medical University of Vienna | Terminated | No outcome recorded |
| Phase 2/3 | NCT03534661 Comparator | Sep 2017 → Mar 2019 | hyperlipidemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01744236 Background | Apr 2013 → Aug 2015 | type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | Missed primary |
| — | NCT00914394 Comparator | Oct 2010 → Jul 2011 | — | Medical University of Vienna | Terminated | No outcome recorded |
| — | NCT00806741 Comparator | Sep 2009 → Mar 2010 | — | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00580957 Background | Aug 2008 → May 2015 | obesity disorder | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-NMMA | “Then, a research medication, L-NMMA, which blocks NO in the blood vessel, will be dripped into the same artery followed by another medication nitroprusside, which gives back...” NCT00240058 ↗38“L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment.” NCT02936687 ↗ “The NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA; 0.2 mg x min(-1) x dL(-1) intra-arterially) also restored the norepinephrine sensitivity.” PMID 16864730 ↗ Jul 2006 “INTERVENTION: Tilarginine (L-N(G)-monomethylarginine [L-NMMA]), 1-mg/kg bolus and 1-mg/kg per hour 5-hour infusion, vs matching placebo.” PMID 17387132 ↗ Mar 2007 “Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure” NCT00344734 ↗ “NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology.” NCT02936687 ↗ “We plan to study this with two drugs -trimethaphan and L-NMMA.” NCT00580957 ↗ “L-N^G monomethyl arginine (L-NMMA)” NCT00759707 ↗ “NG-monomethyl-L-arginine (L-NMMA)” NCT00406731 ↗ “NG-monomethyl-L-arginine (L-NMMA)” NCT00914394 ↗ “NG-monomethyl-L-Arginine (L-NMMA)” NCT00431665 ↗ |
| Known as | L-NG-monomethyl arginine | “INTERVENTION: Tilarginine (L-N(G)-monomethylarginine [L-NMMA]), 1-mg/kg bolus and 1-mg/kg per hour 5-hour infusion, vs matching placebo.” PMID 17387132 ↗ Mar 20074“Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min.” NCT01060930 ↗ |
| Known as | N(G)-monomethyl-L-arginine | “Measurements were repeated after intra-arterial infusion of tetraethylammonium chloride (TEA; 1 µmol/min), fluconazole (0.4 µmol·min(-1)·l(-1)), and N(G)-monomethyl-L-arginine...” PMID 24925526 ↗ Jun 201416“However, we found that AF patients (n=14) were more sensitive to the pressor effects of the NO synthase inhibitor N(G)-monomethyl-l-arginine, suggesting increased NO function...” PMID 18426998 ↗ Apr 2008 “Previous studies using an NO synthase inhibitor, NG-monomethyl-L-arginine (L-NMMA) did not fully determine the NO contribution to blood pressure because of baroreflex buffering.” PMID 39090323 ↗ Aug 2024 “The NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA; 0.2 mg x min(-1) x dL(-1) intra-arterially) also restored the norepinephrine sensitivity.” PMID 16864730 ↗ Jul 2006 “Infusion of NG-monomethyl-L-arginine (L-NMMA; 6.4 µmol/min) into hand veins can cause a 20% increase in vein size in specific subjects.” PMID 21566204 ↗ May 2011 “the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, n=7)” PMID 20484484 ↗ May 2010 |
| Known as | N-mono.methyl-L-arginine | “Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min)” NCT02966665 ↗1“L-NMMA (N-mono.methyl-L-arginine)” NCT00410085 ↗ |
| Known as | Tilarginine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00112281 ↗ |
| Action | Inhibit | “LNMMA inhibits production of nitric oxide” NCT00004575 ↗ |
| Route | Other | “Small doses of four drugs-bradykinin, sodium nitroprusside, miconazole, and LNMMA-will be given through the arterial catheter” NCT00004575 ↗ |